Tin tức & Cập nhật

Chỉ hiển thị Multimedia

FMT reduces alcohol cravings, relapse rates in patients with ALD

Faecal microbiota transplantation (FMT) significantly improves alcohol abstinence and reduces relapse episodes for up to 6 months in patients with alcohol-related liver disease (ALD) and alcohol use disorder (AUD), as shown in a recent study presented at EASL 2026.

FMT reduces alcohol cravings, relapse rates in patients with ALD

một ngày trước

Acute-phase corticosteroid therapy linked to long COVID

15 Jun 2026 bởi

Among patients hospitalized with severe SARS-CoV-2 infection, acute-phase systemic corticosteroid exposure is associated with greater odds of long COVID symptoms, according to a study.

Acute-phase corticosteroid therapy linked to long COVID

15 Jun 2026

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

15 Jun 2026

An updated analysis of the IMbrave050 study reveals no sustained benefit on recurrence-free survival (RFS) among patients with high-risk hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Moreover, data on overall survival (OS) remains incomplete.

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

15 Jun 2026

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

13 Jun 2026

The use of low-dose rivaroxaban among patients with advanced chronic kidney disease (CKD) and high cardiovascular (CV) risk does little to reduce the risk of adverse CV events and may even contribute to increased bleeding events, according to the TRACK randomized clinical trial.

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

13 Jun 2026

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026 bởi

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

12 Jun 2026 bởi

Immunotherapy directed at desmocollin-3 (DSC3) safely improves outcomes in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) expressing DSC3, reports a study presented at ASCO 2026.

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

12 Jun 2026

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

12 Jun 2026

Administering influenza vaccine concomitantly with pertussis-containing vaccine during pregnancy does not contribute to increased risk of adverse pregnancy outcomes, as reported in a retrospective study.

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

12 Jun 2026

Original New Drug Application Approvals by US FDA (16-31 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 16-31 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2026)

12 Jun 2026

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

11 Jun 2026

High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

11 Jun 2026

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

FMT reduces alcohol cravings, relapse rates in patients with ALD

FMT reduces alcohol cravings, relapse rates in patients with ALD

Acute-phase corticosteroid therapy linked to long COVID

Acute-phase corticosteroid therapy linked to long COVID

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

Original New Drug Application Approvals by US FDA (16-31 May 2026)

Original New Drug Application Approvals by US FDA (16-31 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

High-dose influenza vaccine linked to reduced hospitalization risk in older adults